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1. Introduction 
Ammonia plays a major role in the pathogenesis of hepatic encephalopathy (HE). Systemic 
hyperammonemia has been largely found in patients with HE with underlying cirrhosis and 
acute liver failure. HE is associated with a poor prognosis of both acute and chronic liver 
disease (Bustamante, Rimola et al. 1999; Hui, Chan et al. 2002). Cirrhosis is the major cause 
of chronic liver dysfunction and affects 6.5 million people worldwide (Eurostat. 2010, as 
cited in Albrecht, 2010). HE is the hallmark for acute liver failure (ALF), a syndrome with 
very high mortality in which liver transplant is the often the only effective treatment. 
The HE pathophysiological mechanisms include alterations of blood brain barrier function 
cytokine production, ammonia-induced changes in neurotransmitter synthesis and release, 
neuronal oxidative stress, impaired mitochondrial function and osmotic disturbances 
resulting from astrocytic metabolism. However, none of the metabolic discoveries have yet 
lead to a therapy which improves prognosis. In the clinic, liver transplantation remains the 
only curative therapeutic option. Cytotoxic brain edema and intracranial hypertension 
occurring in encephalopathic ALF patients account for a large number of deaths owing to 
cerebral herniation. It has been shown that in chronic liver failure there is a low grade brain 
edema (Andrade, Lucena et al. 2005) that is resolved after transplantation. In comatose 
patients, moderate hypothermia using cooling blankets to depress energy consumption in 
the brain seems to be the only relatively effective palliative therapy, but it is expensive, 
difficult to implement, and not routinely available (Stravitz, Lee et al. 2008; Albrecht 2010). 
Studies focusing on inter-organ ammonia metabolism in patients with cirrhosis indicate that 
the liver, muscles, kidney and the small bowel are important in regulating the circulating 
levels of ammonia. Historically it was thought that the majority of ammonia was produced 
by gut bacteria, and treatment regimens including non-absorbable antibiotics and enemas 
have been extensively used. Contrary to popular belief, it has now been shown that at least 
50-60% of total gut ammonia is derived from uptake of glutamine, which is metabolized to 
glutamate and ammonia by the enzyme glutaminase (GA) (Olde Damink, Jalan et al. 2002; 
Romero-Gomez, Ramos-Guerrero et al. 2004). Ammonia that would normally be converted 
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to urea by a healthy liver increases to toxic levels. In this situation, the enzyme glutamine 
synthetase (GS) plays a pivotal role in ammonia detoxification, effectively removing 
ammonia during the conversion of glutamate to glutamine (Rose, Michalak et al. 1999). 
Glutamine deamidation by intestinal GA seems to be the main source of ammonia in 
patients with cirrhosis (Olde Damink, Jalan et al. 2002), and hyperammonaemia and hepatic 
encephalopathy can appear without the participation of gut bacteria (Weber and Veach 
1979).  
The following data support the hypothesis that a genetic factor is implicated in the 
development of overt hepatic encephalopathy: Glutaminase activity has been linked to 
hepatic encephalopathy and ammonia production; 40% of persons with cirrhosis and 
minimal hepatic encephalopathy do not develop overt hepatic encephalopathy in long-term 
follow-up (Romero-Gomez, Boza et al. 2001); patients with cirrhosis who have the same 
degree of liver dysfunction and the same precipitating factor (for example, variceal 
bleeding) may or may not develop overt hepatic encephalopathy; and at least 2 different 
polymorphisms in the promoter region of the glutaminase gene influence protein activity by 
increasing or decreasing glutaminase activity (Taylor L 2001). 
In this chapter we analyze the studies supporting the inhibition of glutaminase based in the 
identification of mutations in the glutaminase gene to facilitate selection of patients for close 
monitoring and evaluation for expedited transplantation. Firstly, we have identified a 
variant in the promoter region of the glutaminase gene that increases glutaminase activity 
and is associated with the development of HE. Following a simple blood test to identify 
these patients with the variant, it would be possible to offer a treatment with glutaminase 
inhibitors. Based on these and another studies we have developed a new molecule, THDP17 
that inhibits glutaminase in CACO-2 cell cultures (intestinal cells). 
An alternative treatment to HE is currently being investigated: Ornithine phenylacetate 
(OP). OP is a novel drug that is targeted at reducing ammonia concentration in patients with 
liver disease and therefore a potential treatment for HE (Jalan, Wright et al. 2007). The 
mechanism by which OP directly reduces ammonia levels in cirrhosis is by normalization of 
gut glutaminase activity and concomitant increasing muscle glutamine synthesis activity, 
subsequently trapping the increased glutamine with phenylacetate,and increasing ammonia 
excretion as phenylacetylglutamine in the urine.  
These studies support glutaminase such as focus for new treatments of HE and the 
identification of a genetic variation greatly facilitates the selection of patients for close 
monitoring and evaluation for expedited transplantation. 
2. Glutaminase genetic study 
It has been described that there are two forms of mitochondrial glutaminase in the body, 
liver type glutaminase (L-GA) and kidney type glutaminase (K-GA) or extrahepatic (located 
in other organs such as the intestine). In humans, increased glutaminase activity is localized 
to the duodenum. There are indirect data suggesting that glutaminase activity in the 
enterocyte is increased in cirrhotic patients, as demonstrated by the fact that after oral 
administration of glutamine there is a rapid increase in blood ammonia level in cirrhotic 
individuals but not in healthy controls (Romero-Gomez, Grande et al. 2002). 
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Hyperammonemia is noticably marked in patients with liver cirrhosis with poor liver 
function, but this increase in ammonia production following a glutamine challenge returns 
to normal after liver transplantation and normalization of liver function. The specific 
activity of glutaminase in the enterocyte is a crucial point in the stability of nitrogen 
metabolism in patients with liver cirrhosis. It has been shown that glutaminase activity is 
increased in cirrhotic subjects compared to controls and that this activity is related to the 
presence of encephalopathy and the degree of hepatic dysfunction (Romero-Gomez, Ramos-
Guerrero et al. 2004). Thus, also the accumulation of glutamine in the astrocyte is 
responsible, in large part on the toxicity induced by ammonia (Albrecht and Norenberg 
2006). 
The cDNA of the human renal-type glutaminase (HK-GA) was cloned in 1998 and 
subsequently further cDNAs have been isolated encoding for three isoforms of HK-GA, 
which were designated as K-GA (which is predominantly expressed in kidney, intestine and 
brain but not liver), M-GA (which is expressed only in cardiac and skeletal muscle), and  
C-GA (which is expressed primarily in cardiac muscle and pancreas but not in brain or 
liver). The K-GA isoform is localized to the kidney and has 669 amino acids, C-GA, a protein 
of 598 amino acids and differs from the K-GA in the carboxyl terminus and the M-GA is a 
protein of 169 amino acids, which is identical to C-GAP up to amino acid 161 only varying 
for the c-terminal 8residues. After sequencing the genomic DNA, it was proposed that the 
three isoforms were the product of alternative splicings of the same gene. Recently 
described two haplotypes of this gene: TACG and CACG, which place a lower activity of 
glutaminase, which results in lower intestinal production of ammonia and improved liver 
function and lower risk of developing hepatic encephalopathy (Romero-Gomez 2005). 
We assessed whether alterations in the glutaminase gene could explain, at least in part, the 
risk for overt hepatic encephalopathy in patients with cirrhosis. We have described a 
variation in the promoter region of the glutaminase gene that is associated with 
development of HE in patients with cirrhosis (Romero-Gomez, Jover et al. 2010).  
This study included subjects from outpatient clinics from 6 Spanish hospitals: 109 
consecutive patients with cirrhosis in the estimation cohort, 177 patients in the validation 
cohort, and 107 healthy control participants. Patients were followed every 3 or 6 months 
until the development of hepatic encephalopathy or liver transplantation, death, or the end 
of the study.  
The genetic analyses showed that glutaminase TACC and CACC haplotypes were linked to 
the risk for overt hepatic encephalopathy. Mutation scanning of the glutaminase gene 
identified a section in the promoter region where base pairs were repeated (a microsatellite). 
Over a mean follow-up of 29.6 months, hepatic encephalopathy occurred in 28 patients 
(25.7%) in the estimation cohort. Multivariable Cox models were used to determine the 
following independent predictors: Child–Turcotte–Pugh stage (hazard ratio [HR], 1.6 [95% 
CI, 1.29 to 1.98]; P=0.001), minimal hepatic encephalopathy (HR, 3.17 [CI, 1.42 to 7.09]; 
P=0.006), and having 2 long alleles of the microsatellite (HR, 3.12 [CI, 1.39 to 7.02]; P=0.006). 
The association between 2 long alleles of the microsatellite and overt hepatic 
encephalopathy was confirmed in a validation cohort (HR, 2.1 [CI, 1.17 to 3.79]; P=0.012). 
Functional studies showed higher luciferase activity in cells transfected with the long form 
of the microsatellite, which suggests that the long microsatellite enhances glutaminase 
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transcriptional activity. In Figure 1 is shown that patients with long microsatellite showed 
higher risk of overt hepatic encephalopathy. 
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Fig. 1. Actuarial curve showing patients free of bouts of overt hepatic encephalopathy 
according to the microsatellite in the promoter region. Patients with long microsatellite 
showed higher risk of overt hepatic encephalopathy (log-rank: 7.74; p<0.01) 
3. Effects of Ornithinephenylacetate on glutaminase activity in bile duct rats: 
Inflammation and ammonia 
In cirrhotic patients it has been shown that the effects of hyperammonemia are synergistic 
with inflammation (Shawcross, Davies et al. 2004). The effects on cell swelling by cytokines 
in ammonia-sensitized cultured astrocytes has also been shown (Rama Rao, Jayakumar et al. 
2010). However, the mechanisms by which ammonia produces brain swelling are still 
subject of much investigation. Although the effects on inflammatory processes have been 
found to contribute to the formation of cerebral edema, it is not clear whether ammonia 
promotes inflammation or both are independent factors. Inflammatory pathways identified 
as contributing to the edema include cyclo-oxygenase, nitric oxide (NO)/cyclic guanosine 
monophosphate (cGMP) signaling and cytokine release (Andrade, Lucena et al. 2005; 
Montoliu, Piedrafita et al. 2009; Montoliu, Rodrigo et al. 2010).  
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Hyperammonemia could increase blood-brain-barrier permeability to systemic cytokines. It 
is also possible that several factors associated with the systemic inflammatory response 
syndrome could modulate brain dysfunction induced by hyperammonaemia. These 
processes, together with a genetic factor, may help to explain the differences that sometimes 
exist between lower ammonia levels and observed brain impairment in some patients. It has 
been shown that the presence of HE grade 3/4 correlates better with inflammation than with 
ammonia plasma levels (Shawcross, Sharifi et al. 2010), though extracellular brain ammonia 
levels may be significantly higher. One recent study showed that in a cirrhosis animal model 
in which plasma and brain cytokines were markedly elevated following administration of 
lipopolysaccharide (LPS), pre-treatment with OP prevented increased levels of TNFα and 
IL-6 (trend) in plasma and in brain observed in the control group (Wright G 2010). 
Moreover, OP reduced LPS induced development of pre-coma/coma and worsening of 
brain edema. It is well-known that the transcription of NFkB directly increases pro-
inflammatory cytokines and leads to induction of nitric oxide synthase. (Li and Verma 2002). 
OP reduced iNOS and NFkB expressions in the cortical brain region of cirrhotic animals, 
indicating that ammonia reduction may modulate neuroinflammation. In cirrhosis a 
paradox exists between reduced intrahepatic NO generation and excess NO in the 
splanchnic circulation. Splanchnic vasodilatation leads to vasoconstriction of numerous 
vascular beds, including the liver, kidneys, and has significant effects on the brain. 
Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of eNOS (endothelial 
nitric oxide synthase), the levels of which are increased in liver failure (Leiper, Nandi et al. 
2007; Mookerjee, Malaki et al. 2007). It has been shown that treatment of cirrhotic rats with 
OP resulted in restoration of the NOS pathways which may have a direct effect on cerebral 
perfusion (Balasubramaniyan, Wright et al. 2011).  
Physical symptoms of HE and minimal HE have been detected by motor-evoked potentials 
(MEP) which examines the function of signal transmission along the nerve, which is 
perturbed by low grade brain edema. Similar disturbances have been found in patients with 
cirrhosis using magnetic resonance (MR), with signs compatible with low-grade edema 
along the corticospinal tract. These abnormalities were related to functional impairment 
detected by transcranial magnetic stimulation and were found to be reversed after liver 
transplantation. Recently the assessment of MEP in awake rats has been validated to 
monitor HE in animal models of liver failure (induced by portocaval anastomosis-PCA) and 
precipitated HE (simulated gastrointestinal bleed-GB). These models have been utilized to 
test the efficacy of OP, demonstrating that OP treatment prevents the neurophysiological 
abnormalities induced by a GB insult in PCA animals. Administration of OP over differing 
time periods (between 3 hours and 3 days) as a pretreatment prevents the decrease in the 
amplitude and increase in MEP latency at 6 hours post GB (Oria M, Romero-Gimenez J et al. 
2011).  
In preliminary studies, it has been shown that the combination of ornithine with 
phenylacetate to treat hyperammonaemia in cirrhosis is effective in animal models. 
Administration of OP results in increased conversion of glutamate to glutamine by 
stimulation of GS activity in the muscle with the subsequent excretion of 
phenylacetylglutamine in the urine. GA has been found to contribute to hyperammonaemia 
in cirrhosis and in hyperammonaemia animal models (Romero-Gomez, Grande et al. 2004; 
Romero-Gomez, Jover et al. 2006). 
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In this novel approach to target the altered interorgan ammonia metabolism in liver failure, 
OP utilizes the activity of GS to trap ammonia as glutamine, then phenylacetate facilitates its 
excretion as phenylacetylglutamine (Davies, Wright et al. 2009; Ytrebo, Kristiansen et al. 
2009). The effectiveness of this approach with OP has been confirmed in animal models of 
cirrhosis and ALF. The reduction (≈50%) of plasma ammonia was associated with (a) an 
improvement in grade of HE in cirrhotic patients and (b) a reduction in ICP in acute liver 
failure. OP treatment significantly reduced ammonia concentrations, which was associated 
with a reduction in brain water and an increase in myoinositol levels, indicating an 
improvement in brain metabolism (Jalan, Wright et al. 2007; Davies 2009; Ytrebo LM 2009).  
In a devascularised pig model of ALF, the rise in arterial ammonia was attenuated with OP 
which was accompanied by a significant decrease in extracellular brain ammonia and 
prevention of intracranial hypertension (Ytrebo, Sen et al. 2006). 
In our studies we included twenty-five male Sprague-Dawley rats: 4 sham operated, and 21 
BDL. 5 BDL’s received OP (5 days, IP 0.6 g/kg), 5 BDL’s received ornithine (5 days, IP 0.6 
g/kg), 5 BDL’s received phenylacetate (5 days, IP 0.6 g/kg) and 6 received saline (IP). We 
measured plasma levels for: ammonia and standard biochemical markers. Expressions of 
GS, GA and ornithine amino transferase (OAT) were determined by Western-blot 
(expressed as a % of sham values) and enzyme activity was determined by end-point 
methods in liver, kidney, gut, muscle and lung. We found that plasma ammonia was 
decreased in BDL-OP rats vs. BDL-saline (58.97±6.02 vs. 106.2±20.56 µmol/L;P<0.05). BDL-
OP rats showed increased GS expression in liver (66% BDL-OP vs. 55% BDL-saline; P < 0.01) 
and showed further increased levels in the muscle (153% BDL-OP vs.142% BDL-saline). OP 
ameliorates the BDL related increases in glutaminase expression (124%vs.163%; P<0.05) and 
activity (0.45±0.16mIU/mg protein BDL-OP vs. 1.14±0.046mIU/mg protein BDL-saline; 
P<0.01) in gut. We demonstrated that this prevention is due to effect of ornithine in 
glutaminase activity (0.46±0.17mIU/mg protein BDL-O vs. BDL-saline; P<0.05) and not to 
phenylacetate. OP treatment in BDL rats increased the conversion of glutamate to glutamine 
by stimulation of GS in the muscle and also resulted in normalization of glutaminase 
expression and activity in the gut, indicating that OP effectively restricts the production of in 
vivo ammonia in a cirrhotic. Mechanism of action of OP on the metabolism of ammonia is 
shown in the Figure 2. 
4. THDP-17: Glutaminase inhibitor in CACO-2 cultures 
It has been described as a glutaminase inhibitors Mersalyl, N-ethylmaleimide and 6-diazo-5-
oxo-L-norleucine (DON). DON has been used in the inhibition of glutaminase in cell 
cultures of astrocytes in studies demonstrating the importance of GA activity in cell damage 
induced by ammonia. Also, in rats subjected to portocaval shunt, neomycin inhibits 
intestinal glutaminase activity (Hawkins, Jessy et al. 1994), although the mechanisms by 
which neomycin may inhibit glutaminase activity are not described. GA activity is increased 
in patients with high levels of nitric oxide, glucagon, or tumor necrosis factor, and in a wide 
number of cancer types as in liver, breast and leukemia as glutamine is implied as a factor in 
in cell proliferation (Perez-Gomez C 2005; Gao P 2009). 
So based on the above and in the previous studies of assosiation of the presence of long- 
long microsatellite in the glutaminase gene and the mechanism of action of OP in gut  
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Fig. 2. Mechanism of action of OP in glutamine synthetase (GS) and glutaminase (GA) 
enzymes. GS is stimulated in muscle by glutamate increased levels. At the same time PAGN 
is formed and excreted in the urine. In adition, GA is restored to normal levels in the gut 
glutaminase, the inhibitition of glutaminase activity is a therapeutic target in the 
management of hepatic encephalopathy. It is very important to investigate new molecules 
for the purpose of decreasing the intestinal production of ammonia, since it determines a 
high risk of encephalopathy and decreased survival. However, when developing these 
inhibitory molecules is necessary to note that complete inhibition of the enzymatic activity 
of glutaminase could severely damage the normal function of the enterocytes, so that 
molecules inhibiting the activity of glutaminase should cause a reduction in activity ie, a 
partial inhibition of enzyme activity, without significantly affecting the functionality of the 
enterocyte. 
Colon carcinoma cell cultures (CACO2) have been used to test this compound. 50,000 cells 
per well were used in a 12-well plate with 1.2ml DMEM medium supplemented with 2mM 
L-Glutamine, 15% FBS, 1X antibiotic/antifungal solution, 1X non-essential amino acids 
(PAA Laboratories GmbH, Linz, Germany). Plates were incubated at 37°C and 5% CO2 for 
24 and 48h. THDP-17 and 6-diazo-5-oxo-norleucina (DON) (Sigma, St. Louis, EE.UU.) were 
assayed in duplicates at 0, 5, 20 and 100µM. The glutaminase activity was assayed using the 
protocol described by Heini (Heini Hans G. 1987). 
Using both THDP-17 and DON (positive control) 100µM, glutaminase activity was inhibited 
after 48h. The product THDP-17 reduces 42% of the initial glutaminase activity, while DON 
reduces 46% of the initial activity. Therefore THDP-17 is considered to have potential to act 
as a therapeutic option for the hepatic encephalopathy as a glutaminase partial inhibitor that 
is able to cross the cellular and mitochondrial membranes. Further studies to evaluate 
toxicity and in vivo experiments to as certain efficacy need to be done in the future. In Figure  
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3 it can be seen that glutaminase activity is inhibited at 48 hours with differing concentrations 
of THDP-17 and DON (0,5,20 and 100µM). 
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Fig. 3. Inhibition of GA activity following 48 hrs incubation with either THDP 17 or DON in 
Caco-2 cells 
5. Future research 
Glutaminase plays a major role in the cause of hepatic encephalopathy. However, a 
prospective study is required to evaluate the clinical utility of the genetic marker we have 
identified for predicting overt hepatic encephalopathy before it can be recommended for 
clinical practice.  
In the gut, intestinal glutaminase activity is increased in patients with cirrhosis and 
correlates with minimal hepatic encephalopathy (Romero-Gomez, Ramos-Guerrero et al. 
2004). Glutaminase is also a key factor in the brain. Glutamine synthesis detoxifies ammonia 
in the brain, but glutaminase transforms glutamine into ammonia, glutamate, and free 
radicals in the mitochondria, and these byproducts are implicated in mitochondria 
dysfunction and further neurotransmission impairment (Trojan horse hypothesis) (Albrecht 
and Norenberg 2006).  
Studies to date have indicated that OP is safe and patient studies in minimal HE and HE are 
needed to establish whether OP or glutaminase inhibitors such TPHD-17 (a promising GA 
inhibitor) could be used as a treatment for this significant complication of liver disease. 
6. Conclusion 
We identified a microsatellite in the promoter region of the glutaminase gene that is linked 
to the development of overt hepatic encephalopathy in patients with cirrhosis. This 
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promoter is associated with an increase in enzyme activity when the long allele is present. 
This genetic marker might help identify patients at risk for overt hepatic encephalopathy so 
that they could be more carefully monitored and could receive intensive treatment and/or 
define priority in liver transplant waiting list. However, additional studies are needed 
before this biomarker can be recommended for use in clinical practice. 
Our studies support the role of glutaminase in HE and the use of OP, a novel treatment in 
developing for HE in reducing plasma ammonia. The mechanism by which OP directly 
reduces ammonia levels in cirrhosis is by increasing muscle GS activity, subsequently 
trapping and increasing ammonia excretion as phenylacetylglutamine, with the concomitant 
normalization of gut GA activity. The reduction on ammonia (by OP) leads to a reduction in 
ICP in ALF and is associated with an improvement in inflammation in the context of chronic 
liver disease. Moreover, OP modulates iNOS and NFkB mechanisms and prevents LPS-
induced brain edema in cirrhotic rats. 
And finally, we present a new molecule, THDP-17 as a new therapeutic option for the 
treatment of hepatic encephalopathy as a GA partial inhibitor that is able to cross the 
cellular and mitochondrial membranes. 
In summary, we believe that further investigation of GA is warranted, because increased 
knowledge of the pathways involved might lead to the uncovering of new drug targets 
(such as OP and THDP-17) and other treatments for hepatic encephalopathy. These findings 
suggest developing approaches to target GA to prevent ammonia release and subsequent 
HE as a valid therapeutic strategy in the management of patients with liver disease. 
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